Brief: UCB And Biogen Announce Positive DZP Phase 3 Study Results
BRIEF-UCB And Biogen Announce Positive DZP Phase 3 Study Results June 1 (Reuters) - Ucb SA UCB.BR:
UCB AND BIOGEN ANNOUNCE PUBLICATION IN LANCET OF POSITIVE DAPIROLIZUMAB PEGOL (DZP) PHASE 3 STUDY RESULTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
RESULTS SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN DISEASE ACTIVITY WITH DZP VERSUS PLACEBO
Source text: https://tinyurl.com/be5uxddb
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsEurope Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside
Brief: UCB Says CIMZIA Delivered Consistent Effect In Rheumatoid Arthritis
Brief: UCB Said Dapirolizumab Pegol Shows Potential To Reduce Flare Rates
Brief: UCB Presents Bimzelx Data At Eular 2026